Hydroxychloroquine and Acute Generalized Exanthematous Pustolosis

Main Article Content

Justine Galambus
University of South Florida

Atefah Vafa
Department of Rheumatology, University of South Florida

Keywords

acute generalized exanthematous pustulosis, hydroxychloroquine, drug reactions

Abstract

Acute generalized exanthematous pustulosis (AGEP) is a rare, potentially lethal, cutaneous reaction most commonly precipitated by drugs. Removal of the offending drug or treatment of the underlying infection usually results in recovery, though corticosteroids are often used to bolster treatment. We report a case of hydroxychloroquine-induced AGEP in an adult female. Though removal of hydroxychloroquine (HCQ) did largely resolve her rash, she continued to require corticosteroids over 200 days after she first began taking HCQ.

References

1. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Case Control Study. Br J Dermatol. Nov 2007;157(5):989-96. doi:10.1111/j.1365-2133.2007.08156.x

2. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Review. Toxicology. Apr 15 2005;209(2):123-9. doi:10.1016/j.tox.2004.12.022

3. Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Review. Semin Immunopathol. Jan 2016;38(1):75-86. doi:10.1007/s00281-015-0540-2

4. Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. Case Report. J Am Acad Dermatol. Apr 2004;50(4):650-1. doi:10.1016/s0190-9622(03)02733-6

5. Castner NB, Harris JC, Motaparthi K. Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine. Case Report. Dermatol Ther. Sep 2018;31(5):e12660. doi:10.1111/dth.12660

6. Matsuda-Hirose H, Sho Y, Yamate T, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate. Case Report. J Dermatol. Feb 2020;47(2):e53-e54. doi:10.1111/1346-8138.15185

7. Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Article. Dermatol Ther. May 2020;33(3):e13380. doi:10.1111/dth.13380

8. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. Review. J Am Acad Dermatol. Nov 2015;73(5):843-8. doi:10.1016/j.jaad.2015.07.017

9. Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Case Report. Cutis. Mar 2016;97(3):212-6.

10. Delaleu J, Deniau B, Battistella M, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. Case Report. J Allergy Clin Immunol Pract. Jun 7 2020;doi:10.1016/j.jaip.2020.05.046

11. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. Mar 2020;16(3):155-166. doi:10.1038/s41584-020-0372-x

12. Elavarasi A, Prasad M, Seth T, et al. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. J Gen Intern Med. Nov 2020;35(11):3308-3314. doi:10.1007/s11606-020-06146-w

Article Sidebar

PDF
Published
May 6, 2022
DOI https://doi.org/10.25251/skin.6.3.12

Article Details

How to Cite
Galambus, J., & Vafa, A. (2022). Hydroxychloroquine and Acute Generalized Exanthematous Pustolosis. SKIN The Journal of Cutaneous Medicine, 6(3), 246–249. https://doi.org/10.25251/skin.6.3.12
Issue
Vol. 6 No. 3 (2022)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.